Medtronic plc reported 12-month data from a large, multicenter, randomized controlled clinical trial affirming the superiority of differential target multiplexed spinal cord stimulation (DTM SCS) in relieving chronic back pain, vs. traditional SCS therapy, using its Intellis platform.
Abbott Laboratories has won the U.S. FDA’s nod for an iOS-compatible app that is designed to optimize care for people using the company’s neuromodulation devices to manage their chronic pain and movement disorders. The digital tool, which can be used on several Apple devices, is part of Abbott’s Neurosphere Digital Care connected care management platform, which launched in May.
A first-of-its-kind clinical trial conducted by digital health startup AppliedVR suggests the computer-based technology is both feasible and effective for treating chronic pain in a patient’s own home.
SAN FRANCISCO – After slowing growth starting in mid-2018 and a court battle with Boston Scientific Corp. that ended in a favorable resolution, 2019 was a much better year for pain neurostimulation player Nevro Corp., as it launched a major new product. So far, 2020 is looking up too. Its shares (NYSE:NVRO) gained 5% following a presentation at the J.P. Morgan (JPM) Healthcare Conference, where it preannounced 2019 revenues and offered 2020 guidance.
Spinal cord stimulation to treat pain has long been associated with mixed efficacy and substantial side effects such as paresthesia, which is an unpleasant tingly or prickly sensation. Redwood City, Calif.-based Nevro Corp. famously has built a multi-billion-dollar business on next-gen, pain neurostimulation technology that improves efficacy and reduces side effects. Sommerville, Mass.-based Micro-leads Medical Inc. hopes that it could be next in successfully further refining spinal cord stimulation.
